LY117018 shows antiproliferative effects on breast cancer cell lines. LY117018 is a Raloxifene analog and is a selective estrogen receptor modulator.

LY117018 (1 μM) treatment, caused a predominantly hypophosphorylated pRb. At a higher concentration of LY117018 (1 μM), the level of p53 appeared to decline. LY117018 (0.01-1000 nM; 24 hours) at lower concentrations (0.01-10 nM) caused an E2-like increase in p53 levels when compared to its effects on cells grown in the stripped medium. LY117018 did not block E2-induced pRb phosphorylation, at lower concentrations[1]. LY117018 (1 μM; 96 hours) suppresses MCF-7 cell proliferation with an IC50 of 1 μM[2]. LY117018 inhibits oxidative stress-induced endothelial cell apoptosis through activation of ERK1/2 signaling pathway[3].